Inventiva 미래 성장

Future 기준 확인 2/6

Inventiva is forecast to grow earnings and revenue by 21.6% and 47.8% per annum respectively while EPS is expected to grow by 31.5% per annum.

주요 정보

21.6%

수익 성장률

31.5%

EPS 성장률

Biotechs 수익 성장	8.4%
매출 성장률	47.8%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Good
마지막 업데이트	31 Oct 2024

최근 미래 성장 업데이트

Recent updates

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Sep 27

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Jun 18

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Jun 14

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

Mar 19

수익 및 매출 성장 예측

ENXTPA:IVA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	28	-78	-62	-42	7
12/31/2025	15	-86	-64	-47	7
12/31/2024	6	-86	-98	-82	7
6/30/2024	19	-104	-85	-85	N/A
3/31/2024	21	-107	-84	-83	N/A
12/31/2023	23	-110	-82	-82	N/A
9/30/2023	23	-95	-73	-73	N/A
6/30/2023	22	-80	-64	-64	N/A
3/31/2023	20	-67	-55	-54	N/A
12/31/2022	19	-54	-45	-45	N/A
9/30/2022	14	-55	-50	-49	N/A
6/30/2022	10	-56	-55	-54	N/A
3/31/2022	10	-56	-54	-53	N/A
12/31/2021	9	-50	-48	-48	N/A
9/30/2021	7	-45	-46	-45	N/A
6/30/2021	6	-41	-44	-43	N/A
3/31/2021	5	-36	-35	-35	N/A
12/31/2020	5	-34	-31	-31	N/A
9/30/2020	7	-29	-24	-24	N/A
6/30/2020	10	-25	-17	-17	N/A
3/31/2020	10	-27	-23	-23	N/A
12/31/2019	11	-30	-29	-28	N/A
9/30/2019	9	-34	-33	-33	N/A
6/30/2019	7	-37	-38	-38	N/A
3/31/2019	8	-35	-36	-35	N/A
12/31/2018	7	-33	-35	-34	N/A
9/30/2018	8	-29	-28	-27	N/A
6/30/2018	9	-25	-21	-21	N/A
3/31/2018	9	-22	N/A	-19	N/A
12/31/2017	10	-19	N/A	-17	N/A
9/30/2017	11	-16	N/A	-18	N/A
6/30/2017	13	-13	N/A	-19	N/A
3/31/2017	14	-10	N/A	-17	N/A
12/31/2016	14	-7	N/A	-15	N/A
9/30/2016	13	-8	N/A	-14	N/A
6/30/2016	12	-8	N/A	-13	N/A
3/31/2016	10	-9	N/A	-13	N/A
12/31/2015	9	-9	N/A	-14	N/A
12/31/2014	6	-7	N/A	-15	N/A
12/31/2013	5	-7	N/A	-16	N/A

애널리스트 미래 성장 예측

수입 대 저축률: IVA is forecast to remain unprofitable over the next 3 years.

수익 vs 시장: IVA is forecast to remain unprofitable over the next 3 years.

고성장 수익: IVA is forecast to remain unprofitable over the next 3 years.

수익 대 시장: IVA's revenue (47.8% per year) is forecast to grow faster than the French market (5.6% per year).

고성장 수익: IVA's revenue (47.8% per year) is forecast to grow faster than 20% per year.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: Insufficient data to determine if IVA's Return on Equity is forecast to be high in 3 years time

Inventiva 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Consensus revenue estimates increase by 81%, EPS downgraded

Price target decreased by 9.0% to €9.68

Consensus EPS estimates upgraded to €1.21 loss, revenue downgraded

Price target decreased by 20% to €10.64

Consensus revenue estimates increase by 113%

Consensus revenue estimates decrease by 67%

Recent updates

Inventiva Announces the Positive Recommendation of the Fifth DMC of the Nativ3 Phase 3 Clinical Trial with Lanifibranor in Patients with Mash

New major risk - Shareholder dilution

Consensus revenue estimates increase by 81%, EPS downgraded

Inventiva S.A. announced that it expects to receive €348 million in funding from a group of investors

Price target decreased by 9.0% to €9.68

Consensus EPS estimates upgraded to €1.21 loss, revenue downgraded

Inventiva S.A. (EPA:IVA) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

First half 2024 earnings released: €0.94 loss per share (vs €1.32 loss in 1H 2023)

Price target decreased by 20% to €10.64

Consensus revenue estimates increase by 113%

More Unpleasant Surprises Could Be In Store For Inventiva S.A.'s (EPA:IVA) Shares After Tumbling 28%

Shareholders May Not Be So Generous With Inventiva S.A.'s (EPA:IVA) CEO Compensation And Here's Why

Consensus revenue estimates decrease by 67%

Inventiva Announces the Publication in Nature Communications of Additional Results from Native Phase IIb Clinical Trial Demonstrating Improvement of Markers of Cardiometabolic Health in Patients with MASH/NASH Treated with Lanifibranor

Consensus revenue estimates decrease by 21%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Optimistic Investors Push Inventiva S.A. (EPA:IVA) Shares Up 27% But Growth Is Lacking

New minor risk - Share price stability

Inventiva S.A. Provides Update on its Clinical Trial NATiV3

Some Confidence Is Lacking In Inventiva S.A.'s (EPA:IVA) P/S

Consensus EPS estimates fall by 13%

Forecast to breakeven in 2026

Inventiva S.A. to Report First Half, 2024 Results on Sep 25, 2024

Price target decreased by 14% to €15.35

Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program

Price target decreased by 7.4% to €16.50

New major risk - Negative shareholders equity

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 216%

New major risk - Negative shareholders equity

Consensus revenue estimates decrease by 78%

New major risk - Financial position

New minor risk - Shareholder dilution

Consensus revenue estimates decrease by 19%

Inventiva S.A. to Report Fiscal Year 2023 Results on Mar 27, 2024

Consensus revenue estimates increase by 573%

Inventiva S.A. to Report Nine Months, 2023 Results on Sep 28, 2023

New major risk - Revenue and earnings growth

Price target increased by 15% to €18.76

Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD

Analyst Forecasts Just Became More Bearish On Inventiva S.A. (EPA:IVA)

Consensus revenue estimates decrease by 15%

Pinning Down Inventiva S.A.'s (EPA:IVA) P/S Is Difficult Right Now

Consensus revenue estimates decrease by 37%

Revenue Downgrade: Here's What Analysts Forecast For Inventiva S.A. (EPA:IVA)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2025

Inventiva S.A. to Report Fiscal Year 2022 Results on Mar 29, 2023

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis

Inventiva S.A., Annual General Meeting, Jan 25, 2023

Inventiva Announces Lucy Lu as the Director of its Board of Directors

Insufficient new directors

Inventiva Provides Update on Development of cedirogant by AbbVie

Consensus revenue estimates increase by 10%

Consensus revenue estimates increase by 352%

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Inventiva S.A. to Report First Half, 2022 Results on Sep 21, 2022

Inventiva Announces the Screening of the First Patient in LEGEND , Phase IIa Combination Trial with Lanifibranor and Empagliflozin in Patients with NASH and T2D

Despite Lacking Profits Inventiva (EPA:IVA) Seems To Be On Top Of Its Debt

Price target decreased to €19.96

Inventiva Announces Three Scientific Presentations At the EASL International Liver Congress™ 2022

Insufficient new directors

Consensus forecasts updated

No longer forecast to breakeven

Inventiva S.A., Annual General Meeting, May 19, 2022

Inventiva S.A. Announces IND Application for the Phase Ii Combination Trial with Lanifibranor and Empagliflozin in Patients with Nash

Forecast to breakeven in 2024

Inventiva S.A. to Report Fiscal Year 2021 Results on Mar 07, 2022